case_images: PMC5925159_01
case_images: PET scan of the patient at the diagnosis of BRAF-mutant mCRC.
case_images: CRIS2018-8782328.001.jpg
case_images: PMC5925159_01_CRIS2018-8782328.001.jpg
case_images: fig1
case_images: A PET scan revealed bilateral multiple lung metastasis, the biggest being 2.5 cm with an SUVmax value of 12.61, metastasizing from the right colon mass (SUVmax value of 17.19) and with multiple positive lymph nodes (Figures 1 and 2).
case_images: PET scan-correlated CT section of lung nodule at the diagnosis of BRAF-mutant mCRC.
case_images: CRIS2018-8782328.002.jpg
case_images: PMC5925159_03_CRIS2018-8782328.002.jpg
case_images: fig2
case_images: The PET scan result was remarkable with a great response to the tumor (Figure 2).
case_images: PMC5925159_02
case_images: PMC5925159_03
case_images: PET scan-correlated CT section of lung nodule at the diagnosis of BRAF-mutant mCRC.
case_images: CRIS2018-8782328.002.jpg
case_images: PMC5925159_03_CRIS2018-8782328.002.jpg
case_images: fig2
case_images: The PET scan result was remarkable with a great response to the tumor (Figure 2).
case_images: PET scan of the patient on day 45 of the vemurafenib treatment.
case_images: CRIS2018-8782328.003.jpg
case_images: PMC5925159_03_CRIS2018-8782328.003.jpg
case_images: fig3
case_images: The regression of the tumor continued at the control PET scan which is performed 1 month after the previous one, and the PET scan resulted with 3.9 SUVmax value at the primary tumor site. (Figures 3 and 4).
case_images: PET scan correlated CT section of lung nodule on day 45 of the vemurafenib treatment.
case_images: CRIS2018-8782328.004.jpg
case_images: PMC5925159_03_CRIS2018-8782328.004.jpg
case_images: fig4
case_images: The regression of the tumor continued at the control PET scan which is performed 1 month after the previous one, and the PET scan resulted with 3.9 SUVmax value at the primary tumor site. (Figures 3 and 4).
case_images: PMC5925159_04
case_images: PMC5925159_05
case_images: PMC5925159_06